Guangdong Taiantang Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
October 29, 2021 at 05:14 am EDT
Share
Guangdong Taiantang Pharmaceutical Co., Ltd. reported earnings results for the nine months ended September 30, 2021. For the nine months, the company reported sales was CNY 1,446.21 million compared to CNY 2,523.82 million a year ago. Revenue was CNY 1,446.21 million compared to CNY 2,523.82 million a year ago. Net income was CNY 552.73 million compared to CNY 40.53 million a year ago. Basic earnings per share from continuing operations was CNY 0.72 compared to CNY 0.05 a year ago. Diluted earnings per share from continuing operations was CNY 0.72 compared to CNY 0.05 a year ago.
Guangdong Taiantang Pharmaceutical Co Ltd is a company mainly engaged in the manufacturing of Chinese patent medicines and the primary processing of Chinese medicinal materials. The Company operates five segments. Chinese Patent Medicines Manufacturing Business segment is mainly responsible for the production and wholesale of Pibao cream, Qilin pill, Xinbao pill, Xinxin pill, Tongqiao Yixin pill, etc. Primary Processing Business segment of the traditional Chinese medicine materials is mainly responsible for planting, primary processing and sales of the ginseng and traditional Chinese medicine materials. Drug Wholesale and Retail Business segment is mainly responsible for the wholesale and retail of drugs and medical devices. Health Industry Development and Products Sales segment is mainly responsible for the development and sales of health concept real estate products. Medical Services segment is mainly responsible for the in-depth development of medical and elderly care services.